Figure 2.

Targeting B-ALL progression. While evading exposure to environmental factors is challenging, the possibility of preventing B-ALL development lies in the potential elimination of preleukemic cells prone to transformation. Nonetheless, the key lies in discovering a method to specifically target these preleukemic cells. A recent study has paved the way for such a therapeutic approach (71). This proof-of-concept experiment was carried out in a mouse model that mirrors the characteristics of a leukemia-predisposition syndrome (Pax5^+/- mice), which develops B-ALL following exposure to common infections. Temporary administration of the Jak1/2 inhibitor ruxolitinib to Pax5+/− mice significantly diminishes the risk of leukemia occurrence, owing to the reduction of preleukemic cells.